SEOUL, South Korea, May 31, 2023 /PRNewswire/ — Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, ‘JIN-A04’. The total contract size is 325…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.